# Evaluation of the trypanocidal and immunomodulatory effects of LDT409, a cardanol derivative from cashew nut shell liquid

## TL;DR

This study explores LDT409, a compound from cashew nut shell liquid, for its potential to treat Chagas disease by reducing parasite levels and modulating the immune response.

## Contribution

The study introduces LDT409 as a novel cardanol derivative with trypanocidal and immunomodulatory effects for Chagas disease.

## Key findings

- LDT409 reduced peak parasitemia in a murine model of acute Chagas disease.
- Treatment shifted the immune response toward a Th2/Th17 profile and reduced Th1-driven inflammation.
- LDT409 was associated with reduced cardiac damage in infected mice.

## Abstract

Chagas disease (CD), caused by Trypanosoma cruzi, is a neglected tropical illness with significant public health impact, particularly due to its cardiac manifestations. Current etiological treatments, benznidazole and nifurtimox, are limited by prolonged administration, adverse effects, and low cure rates, especially in chronic cases. Natural products, such as cashew nut shell liquid (CNSL), are a promising source of bioactive compounds with trypanocidal and immunomodulatory properties, and the added benefit of low production costs, a valuable advantage in addressing neglected tropical diseases. LDT409, a synthetic saturated cardanol derivative from CNSL, was designed as a fatty acid mimetic and partial agonist of peroxisome proliferator-activated receptors (PPARs), nuclear transcription factors that regulate lipid metabolism and attenuate inflammation by modulating immune responses. In CD, PPARs regulate host–parasite interactions by promoting anti-inflammatory immune polarization, which mitigates tissue-damaging inflammation but may also increase susceptibility to T. cruzi infection.

In this study, we evaluated the trypanocidal activity and immunomodulatory effects of LDT409 using in vitro assays and an in vivo murine model of acute CD.

Our findings indicate that LDT409 treatment was associated with a reduction in peak parasitemia and with modulation of the host immune response, characterized by a shift toward a Th2/Th17 profile and attenuation of a Th1-driven pro-inflammatory response, concomitant with reduced cardiac damage. Notably, the underlying mechanisms of these effects, including the involvement of PPARs, remain to be clarified.

Together, these observations suggest that LDT409 may represent a promising, cost-effective, and sustainable compound for further investigation in the context of Chagas disease.